CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 20 enrolled
Drug / intervention
Cu 64 anti-CEA monoclonal antibody M5A IV +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02293954
NCT02293954N/AActive
CompareCT.gov

Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)

City of Hope Medical Center·interventional·Posted Nov 19, 2014·Updated Nov 14, 2025

In Brief

A clinical study evaluating radionuclide imaging, positron emission tomography, and 3 other interventions for Breast Cancer and 11 related conditions. Active but no longer recruiting, targeting 20 participants across 1 site.

Detailed Summary

This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer. Diagnostic procedures, such as copper Cu 64 anti-CEA monoclonal antibody M5A PET, may help find and diagnose CEA positive cancer that may not be detected by standard diagnostic methods.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastrointestinal Cancer, Liver and Intrahepatic Biliary Tract Cancer, Lung Cancer, Metastatic Cancer, Pancreatic Cancer, Rectal Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/AActive
201520162017201820192020202120222023202420252026
First PostedNov 19, 2014
Enrollment StartNov 11, 2015
Primary CompletionMar 6, 2022
Study CompletionAug 11, 2026
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 11.6 years ago

Interventions

radionuclide imagingprocedure

Given copper Cu 64 anti-CEA monoclonal antibody M5A IV

positron emission tomographyprocedure

Undergo PET

laboratory biomarker analysisother

Correlative studies

pharmacological studyother

Correlative studies

Cu 64 anti-CEA monoclonal antibody M5A IVdrug

Cu 64 anti-CEA monoclonal antibody M5A IV